Back to News
Market Impact: 0.2
10x Genomics Consensus Price Target Increased by 13.66% to $60.62
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for 10x Genomics was raised 13.66% to $60.62 per share from $53.33 as of September 11, 2026. The upward revision indicates improved analyst expectations for the genomics company, though the article provides no underlying earnings, operating, or guidance changes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
TXG0.45
More News
- Cathie Wood’s ARK stock trades: Cerebras and BWX Technologies lead buys
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance